Biocracked
Approach: conceptual metaphor. Palette: bold color field.

Subject: a heavy steel hand-brake lever from a bicycle or machine, shown in tight close-up, half-released with its cable going slack. A taut, braided rope of dense red muscle-like fibers runs through the frame, pulling free of the brake. The surface is lightly scuffed and brushed, with a thin electric green (#00e676) cable sleeve as the one small accent.

Camera: low three-quarter angle, 85mm lens, shallow depth of field, the lever sharp in the foreground and the rope softening behind it.

Lighting: crisp, directional studio light from the upper left, with hard-edged but clean shadows and warm highlights on the metal.

Backdrop: a seamless, saturated mustard-yellow field, evenly lit and uncluttered, with no blue cast anywhere.

Mood: tense but hopeful, a mechanism being released, with a hint of caution in the sharp shadows.
Longevity

Pemblokir Myostatin Ngereduksi Kehilangan Otot Akibat Semaglutide, Ana Cathetan

Dr. Synapse · · 4 min read

Semaglutide bisa ngilangi lemak, nanging uga bisa nyedhot otot bareng‑bareng. Saka uji fase 2 gedhé ing The Lancet, ngendhaleni "rem" pertumbuhan otot awak bisa nyegah kehilangan otot. Hasilé positif, nanging ana watesan lan salah siji varian perawatan nuduhaké sinyal keamanan sing kudu diparani.

Iki sing ditemokaké saka uji COURAGE, apa sing ora ditemokaké, lan apa sing bisa ditindakké pangguna GLP‑1 saiki.

Masalah: Penurunan Bobot Cepet Ora Mung Lemak

Penurunan bobot saka agonis reseptor GLP‑1 nggawa kehilangan otot sing cukup signifikan. Ing uji COURAGE, peserta sing nganggo semaglutide bareng placebo ilang 6,6 % massa lemes ing 26 minggu (95 % CI − 7,4 nganti − 5,7). Ing fase 52 minggu, kelompok placebo malah ilang 7,3 % massa lemes.

Massa lemes ora persis padha karo otot rangka, nanging iku ukuran utama sing digunakaké ing uji lan dadi proksi standar.

Gagasan: Blokir Myostatin (GDF8) lan Activin A

GDF8, sing luwih dikenal minangka myostatin, lan activin A ngléwat reseptor ActRIIA/B minangka regulator negatif massa otot. Regeneron ngetes loro antibodi:

  • Trevogrumab, sing ngalangi GDF8 lan diwènèhi saben minggu kanthi suntikan subkutan.
  • Garetosmab, sing ngalangi activin A lan diwènèhi intravenously saben 4 minggu.

Uji Coba: 975 Wong, Loro Bagian

Studi iki double‑blind, placebo‑controlled fase 2 ing 60 situs ing AS. Nglibataké 975 wong diwasa sing kagungan obesitas (BMI ≥ 30), rata‑rata umur 49 taun lan BMI 36,7. Patang puluh enem persen saka peserta wadon. Kabèh peserta ngombé semaglutide sing dititrasi nganti 2,4 mg seminggu.

  • Bagian A (26 minggu, n=605): placebo, trevogrumab 200 mg, trevogrumab 400 mg, utawa trevogrumab 400 mg + garetosmab 10 mg/kg.
  • Bagian B (52 minggu, n=376): placebo, trevogrumab 25 mg, utawa trevogrumab 75 mg.

Angka Utama: Massa Lemes

Gambar ing ngisor iki nuduhaké beda perlakuan sing diprakiraké dibandhingaké karo semaglutide + placebo.

Bagian A (26 minggu):

  • Trevogrumab 200 mg: +3,1 % (95 % CI 1,9‑4,3)
  • Trevogrumab 400 mg: +2,7 % (1,5‑4,0)
  • Trevogrumab 400 mg + garetosmab: +4,5 % (3,1‑5,9)

Bagian B (52 minggu):

  • Trevogrumab 25 mg: +1,5 % (‑0,3‑3,3), ora signifikan sacara statistik
  • Trevogrumab 75 mg: +3,1 % (1,3‑4,9)

Perlakuan iki ngurangi kehilangan massa lemes, nanging ora ngilangké total. Abstrak ora nyebutaké perubahan absolut massa lemes kanggo kelompok perlakuan, dadi angka "kehilangan net" kudu diprakiraké déwé.

Penurunan Lemak lan Bobot: Kaget

Obat sing ngreksa otot kadang dianggep bakal ngorbanaké penurunan lemak. Ing kasus iki, asilé kebalik.

  • Kelompok placebo ilang 15,6 % massa lemak ing Bagian A.
  • Trevogrumab 400 mg dewekan ngasilaké penurunan lemak sing luwih gedhé (ETD ‑3,4 %).
  • Kombinasi trevogrumab + garetosmab ngasilaké penurunan lemak sing luwih drastis (ETD ‑11,7 %).
  • Bobot awak mudhun 10,6 % ing semaglutide + placebo. Mung kombinasi sing nambahake penurunan bobot ekstra 2,7 poin persén.
  • Ora ana kelompok Bagian A liyané lan ora ana kelompok Bagian B sing béda sacara signifikan ing massa lemak utawa bobot.

Kendala: Profil Keamanan Kombinasi

Trevogrumab dewekan (dosis 25, 75, 200 utawa 400 mg) umume ditoleransi apik, karo profil keamanan sing mirip karo semaglutide + placebo. Efek samping gastrointestinal paling umum lan kedadéané padha ing sakabehe grup. Akeh adverse event sing ringan nganti moderat.

Kelompok trevogrumab 400 mg + garetosmab beda:

  • Adverse event serius: 14 saka 149 (9 %)
  • Penghentian perawatan: 48 saka 149 (32 %)
  • Kram otot: 61 saka 149 (41 %), dibandhingaké 8 % (23 saka 299) ing grup trevogrumab dewekan lan 5 % (7 saka 151) ing placebo
  • Mati: loro kasus sajrone uji, loro‑loro ana ing grup iki. Peneliti ora nemokaké hubungan sebab‑akibat.

Para penulis nyimpulaké yèn kombinasi iki "ora nduwèni keamanan lan tolerabilitas sing apik". Trevogrumab dewekan dipasrahaké minangka bukti konsep.

Cathetan Penting

  • Sponsor: Uji iki dibiayai Regeneron, lan akèh penulisé karyawan lan pemegang saham Regeneron.
  • Fase 2: End‑point utama yaiku komposisi badan lan bobot, dudu fungsi. Penulis nyatakaké butuh studi luwih lanjut kanggo ndelok apa pelestarian massa lemes bakal nambah fungsi fisik lan kesehatan metabolik.
  • Durung disetujui: Ora ana antibodi sing disetujui kanggo panggunaan iki. Sampeyan ora bisa entuk iki minangka suplemen utawa resep.
  • Fase penarikan: Bagian A kalebu periode 26 minggu sawise semaglutide dihentikaké, nanging abstrak ora nyebutaké asilé.

Apa Tegese Karo Pangguna GLP‑1 Saiki

Pituduh iki umum lan dudu asil saka studi iki, amarga ora nyoba olahraga utawa diet.

  • Aja nguber kelas obat iki. Ora ana dosis, jadwal utawa "sapa sing cocok" amarga ora ana sing kasedhiya njaba uji coba.
  • Prioritasaké protein lan latihan tahanan. Iki cara sing paling disaranaké lan gampang diakses kanggo njaga otot nalika ngurangi bobot. Rembugan target protein lan rencana latihan karo dokter utawa ahli gizi, luwih-luwih yen sampeyan nduwèni penyakit ginjal.
  • Lacak luwih saka timbangan. Kekuatan, fungsi lan, yen bisa, komposisi badan menehi informasi luwih akurat tinimbang bobot waé.

Jadwal

Abstrak ora maringi perkiraan wektu persetujuan. Uji COURAGE saiki isih aktif nanging ora nampa pendaftar anyar. Amarga profil keamanan kombinasi iki dadi perhatian lan fungsi ora ditliti, dibutuhaké uji coba luwih lanjut sadurungé regulator bisa nimbang panggunaan obat iki. Anggep iki sinyal awal sing promising, dudu pilihan sing bakal teka cepet-cepet.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: bold color field.

A single ripe, glossy red tomato-colored apple sits at the center of a saturated mustard-yellow seamless backdrop, with a neat row of five identical white capsules lined up beside it on the same surface. The apple is the clear winner of the frame. One capsule has rolled slightly away, cracked open and spilling a tiny pile of pale powder. Shot at a low three-quarter angle with a shallow depth of field, so the back capsules blur softly. Lighting is a large, soft key light from the upper left, giving crisp but gentle shadows with warm yellow bounce. A thin sprig of electric green (#00e676) leaves rises from the apple stem as the only green accent. Mood: confident, playful and skeptical, a clean verdict that real food outweighs pills. No text or labels.
longevity

Suplemen Sel Zombie? 27 Uji Manungsa Nggedhekake Diet Ngluwihake Pil

BY NOVA CHEN ·

Suplemen asring janji bakal "ngresiki sel zombie", nanging tinjauan sistematis saka 27 uji coba manungsa karo 3.811 peserta nuduhaké bukti sing tipis. Pembatasan kalori nuduhaké penurunan sinyal inflamasi sing paling konsisten. Omega‑3 dadi suplemen paling menjanjikan, sanajan bukti isih winates lan campur aduk. Penanda telomer lan p16/p21 ora akeh owah. Iki tegese apa sing kudu dipangan lan apa sing kudu dituku.

Approach: Macro science. Palette: D, bold color field.

An extreme close-up microscopy-style photograph of a single giant megakaryocyte cell, a large lumpy, lobed cell with a textured, slightly translucent surface, budding off dozens of tiny, smooth, disc-shaped platelets that drift away on fine stringy extensions. The cell and platelets are a warm pearly ivory with subtle coral-pink internal granules and a few small electric green (#00e676) fluorescent specks inside, suggesting recycling vesicles. The backdrop is a saturated, even tomato-red to deep orange color field with a soft gradient. Shot from slightly above at a three-quarter angle, with shallow depth of field so the nearest platelets are crisp and the distant ones melt into soft blur. Lighting is clean, diffuse and glowing from behind, giving gentle rim highlights. Mood: curious, precise, quietly cautionary. No text.
longevity

CoQ10 Ngerem Trombosit Lawas ing Tikus Tuwa — Ana Trikane Kene

BY NOVA CHEN ·

Studi anyar ing *Aging Cell* nglaporake yèn CoQ10 nambah fungsi megakariosit lawas ing tikus. Tikus sing diwènèhi CoQ10 nuduhaké agregasi trombosit lan aktivasi sing luwih sithik, sanajan cacah trombosit ora owah. Pengaruh iki katingal liwat COPS3 lan autophagy, sistem daur ulang sel. Nanging riset iki mung ing tikus lan sel laboratorium, ora ana data manungsa lan ora ana bukti pencegahan beku. Mula, wong sing nganggo antikoagulan kudu takon dhokter dhisik.

Approach 2, lab in action, with palette D, bold color field.

Overhead-angled close shot of a gloved hand in a pale purple nitrile glove holding an open agar petri dish above a saturated mustard-yellow lab bench. Inside the dish, dozens of tiny translucent C. elegans worms trace sinuous curved tracks across a faintly glowing bacterial lawn. A small cluster of the worms shows a subtle electric green fluorescence along their bodies, suggesting neurons. Beside the dish, a microcentrifuge tube holds a pale golden-yellow DHM solution, with a pipette tip hovering nearby. Lighting is bright, crisp, directional studio-style lab light with soft short shadows. The shallow depth of field blurs the background to a smooth yellow. The mood is curious, precise and optimistic, with a slightly playful contrast between the vivid backdrop and the delicate, nearly invisible animals.
longevity

Suplemen Hangover DHM Nambah Umur Cacing nganti 15 %

BY NOVA CHEN ·

Senyawa sing dipasarkan ing kapsul hangover iki mung nambah umur cacing nganti 15 %. Ing panaliten anyar nganggo *Caenorhabditis elegans*, dihidromiritin (DHM) uga nglindhungi neuron reseptor sentuhan, njaga gerakan cacing luwih suwe, lan nyuda lemak usus. Efek umur iki ora gumantung marang gen longevity klasik *daf‑16*, lan laporan anti‑oksidan standar ora kebangun, nuduhaké mekanisme sing luwih unik. Nanging iki mung ana ing cacing, konsentrasi mikromolar ora bisa langsung diterjemahaké dadi dosis kapsul manungsa, lan ora ana data umur manungsa.

**Approach: Macro science. Palette: Bold color field (saturated magenta).**

Extreme macro photograph of fisetin-like yellow needle crystals growing from a single point, with two larger, more geometric, translucent amber-gold crystals standing slightly apart as the "upgraded" versions. The crystals show real facets, internal fractures and sharp refractive edges. They rest on a glossy, saturated magenta surface that fills the background in a smooth gradient and reflects a faint mirror image of the crystals. Shot from a low three-quarter angle with a shallow depth of field, so the foreground crystal tips are razor sharp and the rest melts into soft magenta bokeh. Lighting is a crisp, warm-white key from the upper left, with strong specular highlights and a thin rim of electric green (#00e676) light catching one crystal edge. Mood: precise, curious, and slightly skeptical, like a lab specimen under scrutiny.
longevity

Fisetin Ora Cukup Kuat? Ilmuwan Nggawe Loro Turunan Sing Ditingkataké

BY DR. SYNAPSE ·

Peneliti saka Universitas Minnesota nerbitaké artikel ing Aging Cell sing nuduhaké yèn fisetin sing saiki lagi dites klinis duwé efektivitas lan bioavailabilitas winates. Amarga kuwi, tim riset ngembangaké loro turunan flavonoid, SR29384 lan SR31133, sing luwih kuat ngilangi sel senesèn lan nambah kesehatan tikus. Data ing manungsa durung ana, lan senyawa iki ora didol bebas. Penulis uga nerangaké kepemilikan paten lan keterlibatan startup, sing dadi pratondho penting kanggo konsumen fisetin saiki lan sing kudu luwih waspada.

This page is available in